Isofol Medical AB (publ.) is a biotech company working with the development of the cancer drug, arfolitixorin. Arfolitixorin is a new drug candidate that Isofol is primarily developing to treat colorectal cancer (CRC) – the third most common type of cancer and one for which there is a substantial need for more effective drugs. Isofol’s development work with arfolitixorin is also targeting so-called “rescue therapy” after high-dose chemotherapy with methotrexate in conjunction with osteosarcoma (bone cancer). Other potential uses for arfolitixorin also includes the treatment of pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers.
Isofol Medical
Isofol is developing cancer treatment drug arfolitixorin.
